key: cord-0693596-fs4bug57
authors: Quere, Baptiste; Saraux, Alain; Marhadour, Thierry; Jousse-Joulin, Sandrine; Cornec, Divi; Houssais, Camille; Alegria, Guillermo Carvajal; Quiviger, Maxime; Guillou, Margot Le; Devauchelle-Pensec, Valerie; Guellec, Dewi
title: Impact of the COVID-19 pandemic on therapeutic management of rheumatoid arthritis in Brittany (France)
date: 2021-03-27
journal: Joint Bone Spine
DOI: 10.1016/j.jbspin.2021.105179
sha: 7438f7cb97aabd4fba27ee0b2e911ace0d799735
doc_id: 693596
cord_uid: fs4bug57

nan

Early during the SARS-CoV-2 sanitary crisis, the vulnerability of patients treated with immunomodulatory agents or nonsteroidal anti-inflammatory drugs (NSAIDS) with regards to the most severe forms of the disease have been suggested [1, 2] . Despite rapid clarifications from health authorities and expert societies regarding the indication to continue ongoing therapy in most situations, the usual immunosuppressive treatment of several clinical conditions, including inflammatory rheumatic diseases, may have been impacted by these scientific data and their media relay [3] [4] [5] [6] . In the present work, our objectives were to evaluate the impact of COVID-19 pandemic on therapeutic management of rheumatoid arthritis (RA) and to identify factors associated with patient's choice to reduce or stop Disease-Modifying AntiRheumatic Drugs regimen (DMARD).

For this, we conducted a cross-sectional single-center study in Brittany (France) between April 23, 2020 and July 28, 2020. The study received approval from the Brest University Hospital Ethics committee (29BRC20.0110). A questionnaire was administered to patients with a diagnosis of RA satisfying ACR/EULAR criteria, receiving DMARD or having a prescription to initiate such treatment, during face-to-face or remote consultations. The This study shows that in a French area of low viral circulation, the sanitary crisis led to DMARD treatment modification in around 10% of RA patients, a result of the same order as what has been observed elsewhere in comparable contexts [7] [8] [9] [10] . Our results describe the therapeutic modifications that can be highlighted during a classic interview with patients but do not take into account the more complex problematic of non-compliance. In most cases, treatment modification was the consequence of a patient's decision rather than a decision driven by a healthcare professional. Future studies will have to determine the longitudinal impact of COVID-19 pandemic on RA optimal management. 

and non-steroidal anti-inflammatory drugs (NSAID)

Misguided drug advice for COVID-19

Managing patients with rheumatic diseases during the COVID-19 pandemic: The French Society of Rheumatology answers to most frequently asked questions up to

COVID-19 epidemiology in rheumatic diseases in Tuscany: A case-control study

Prevalence of COVID-19 among patients with chronic inflammatory rheumatic diseases treated with biologic agents or small molecules: A population-based study in the first two months of COVID-19 outbreak in Italy

Implications of COVID-19 for the management of patients with inflammatory rheumatic diseases

Treatment adherence of patients with systemic rheumatic diseases in COVID-19 pandemic

Treatment adherence behaviours in rheumatic diseases during COVID-19 pandemic: a Latin American experience

Impact of COVID-19 outbreak on rheumatic patients' perceptions and behaviors: A cross-sectional study

Adherence to medication in patients with rheumatic diseases during COVID-19 pandemic

We would like to thank the clinical research department ("Direction de la Recherche Clinique et de l'Innovation") of the Brest teaching hospital (CHU de Brest), and particularly Marie-Hélène Lallier, for their assistance in the implementation of this project. We also thank all the participants.None of the authors has any conflicts of interest to declare.